IV and Oral Iron Drugs Market
Request Sample Report
IV and Oral Iron Drugs Market Size and Growth
The IV and Oral Iron Drugs market is experiencing significant growth driven by rising iron deficiency anemia prevalence. The global market size reached approximately $8 billion in 2023 and is projected to expand due to increased healthcare access and advancements in drug formulations, addressing patient needs effectively across various demographics. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Daiichi Sankyo Company
◍ Vifor Pharma
◍ Akebia Therapeutics
◍ Allergan
◍ AMAG Pharmaceuticals
◍ AOP Orphan Pharmaceuticals
◍ Pharmacosmos
◍ Sanofi
◍ Shield Therapeutics
◍ AZAD Pharma
◍ Cirondrugs
◍ MEDICE
◍ Pfizer
◍ Salveo Lifecare
◍ Sunny Pharmaceutical
The IV and Oral Iron Drugs Market features key players such as Daiichi Sankyo, Vifor Pharma, and AMAG Pharmaceuticals. These companies drive growth through innovative products, extensive marketing strategies, and strategic collaborations, catering to diverse anemia treatments. Revenue highlights include:
- Pfizer: ~$81 billion (2022)
- Daiichi Sankyo: ~$9 billion (2022)
- AMAG Pharmaceuticals: ~$220 million (2021)
Market Segmentation
By Application
Nephrology ◍ OBGYN
◍ Surgeries
◍ Gastroenterology
◍ Oncology
◍ Heart failure (HF)
By Product
◍ Oral Iron Drug
IVIron Drugs
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
